Uncategorized
Opinion: STAT+: The real work for making dramatic gains against pancreatic cancer is just beginning
On May 31, at the American Society of Clinical Oncology (ASCO) meeting in Chicago, an international study co-led by a UCLA research team reported that patients with pancreatic cancer who took the drug daraxonrasib lived substantially longer, for an average of 13.2 months, compared with 6.6 to 6.7 months for patients who had chemotherapy alone.
This is welcome news, and in anticipation of these results, the FDA, just a month earlier, announced it was granting early access to the drug for selected patients who had failed guideline-directed treatments for this lethal malignancy.
Widespread media coverage of this regulatory pivot in drug access highlights the intense, enduring interest among the general public, as well as in the scientific and medical communities, for identifying treatments that can move the survival needle lethal for complex, heterogeneous malignancies, thereby derailing effective treatment, especially when only single drugs are deployed to improve clinical outcomes.
On May 31, at the American Society of Clinical Oncology (ASCO) meeting in Chicago, an international study co-led by a UCLA research team reported that patients with pancreatic cancer who took the drug daraxonrasib lived substantially longer, for an average of 13.2 months, compared with 6.6 to 6.7 months for patients who had chemotherapy alone.
This is welcome news, and in anticipation of these results, the FDA, just a month earlier, announced it was granting early access to the drug for selected patients who had failed guideline-directed treatments for this lethal malignancy.
Widespread media coverage of this regulatory pivot in drug access highlights the intense, enduring interest among the general public, as well as in the scientific and medical communities, for identifying treatments that can move the survival needle lethal for complex, heterogeneous malignancies, thereby derailing effective treatment, especially when only single drugs are deployed to improve clinical outcomes.
Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.
The U.S. government has argued that it pays too much of biopharma R&D costs, demanding that other high-income countries contribute fairly to global innovation efforts.
Uncategorized
STAT+: Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.
And here is our regular feature in which we highlight a different person each week. This time around, we note that Protego Biopharma hired Jae Kim as chief medical officer. Previously, he held the same roles at Septerna and Design Therapeutics.
But all work and no play can make for a dull chief medical officer.
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.
And here is our regular feature in which we highlight a different person each week. This time around, we note that Protego Biopharma hired Jae Kim as chief medical officer. Previously, he held the same roles at Septerna and Design Therapeutics.
But all work and no play can make for a dull chief medical officer.
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
Denali sells FDA voucher for $195M to support neurodegenerative pipeline
US launches investigation into German drug pricing, citing unfair R&D burden
STAT+: Up and down the ladder: The latest comings and goings
Moderna’s mRNA flu shot wins unanimous support at FDA adcomm in rebuke of former leadership
Memento brings home $93M series A souvenir, picks up bispecific for eye diseases
Opinion: STAT+: The real work for making dramatic gains against pancreatic cancer is just beginning
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State
-
Uncategorized3 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors
-
Contributors9 years ago
The final 6 ‘Game of Thrones’ episodes might feel like a full season